Tag
A major 2026 cluster randomized trial shows that palliative care delivered by trained hepatologists is noninferior to specialist palliative care for improving quality of life in end-stage liver disease, supporting scalable integrated models
The updated AASLD/AST guideline clarifies how adults should be evaluated for liver transplantation, emphasizing equitable access, multidisciplinary assessment, psychosocial readiness, and structured risk–benefit decision-making.
This review analyzes the longitudinal kinetics of 43 inflammatory biomarkers in patients with severe alcohol-associated hepatitis, comparing IL-1 receptor antagonism and corticosteroid therapy, highlighting treatment-specific signatures and
A large-scale longitudinal study reveals that obesity and diabetes synergistically amplify the risk of advanced liver disease in individuals with Alpha-1 Antitrypsin Deficiency (AATD), while also identifying a complex relationship between b
This article summarizes the updated clinical care pathway for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), highlighting new diagnostic nomenclature, risk stratification tools, and the integration of the first FDA-approv
This review synthesizes recent findings identifying the CEBPA-ORM1 axis as a critical suppressor of alcohol-associated liver disease, highlighting its potential as both a therapeutic target and a diagnostic biomarker for disease staging.
The Phenome India study identifies a 38.9% age-adjusted prevalence **Constructing the JSON Object** Now, I’m carefully constructing the JSON object, which needs to be a valid, parseable string. I’m focusing on incorporating the
The 24-week results of the IMPACT trial show that pemvidutide significantly improves MASH resolution without worsening fibrosis. While fibrosis improvement did not reach significance at this early time point, the drug’s safety profile
